Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

86.50USD
14 Dec 2017
Change (% chg)

$-1.39 (-1.58%)
Prev Close
$87.89
Open
$88.22
Day's High
$88.31
Day's Low
$86.12
Volume
891,206
Avg. Vol
898,459
52-wk High
$89.07
52-wk Low
$67.54

Chart for

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.34
Market Cap(Mil.): $95,244.70
Shares Outstanding(Mil.): 1,101.09
Dividend: 0.56
Yield (%): 2.60

Financials

  Industry Sector
P/E (TTM): -- 32.50 16.04
EPS (TTM): -- -- --
ROI: -- 15.11 35.70
ROE: -- 16.59 15.40

UPDATE 1-Boehringer CFO Menne quits in differences over strategy

FRANKFURT, Dec 15 The chief financial officer of unlisted Boehringer Ingelheim, Simone Menne, will quit Germany's second-largest pharmaceuticals company at year-end after just 16 months in office because of differences over strategy.

5:31am EST

BRIEF-NSAV Subsidiary Signs Agreement With Eli Lilly

* NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANY

Dec 14 2017

Lilly's 2018 forecast beats on strength of new drugs

Eli Lilly and Co on Wednesday forecast 2018 profit and revenue ahead of Wall Street estimates on strong demand for recently launched drugs such as Trulicity and Taltz.

Dec 13 2017

Lilly forecasts 2018 profit largely above estimates

Dec 13 Eli Lilly and Co on Wednesday forecast 2018 earnings largely above analysts' estimates in part due to strong demand for recently launched products such as diabetes drug Trulicity and psoriasis drug Taltz.

Dec 13 2017

BRIEF-FDA Accepts Biologics License Application (BLA) To Review Galcanezumab For The Prevention Of Migraine In Adults

* FDA ACCEPTS BIOLOGICS LICENSE APPLICATION (BLA) TO REVIEW GALCANEZUMAB FOR THE PREVENTION OF MIGRAINE IN ADULTS

Dec 11 2017

BRIEF-Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018

Dec 6 NOVO NORDISK A/S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN MADE FOLLOWING COMMENTS DURING AN INVESTOR CALL FOLLOWING U.S. APPROVAL OF DIABETES DRUG OZEMPIC:

Dec 06 2017

FDA approves Novo Nordisk diabetes drug Ozempic

The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.

Dec 05 2017

UPDATE 3-U.S. FDA approves Novo Nordisk diabetes drug Ozempic

Dec 5 The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.

Dec 05 2017

BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14

* Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing Source text: (http://bit.ly/2BcO2L7) Further company coverage:

Nov 22 2017

Lilly mulls sale, other options for animal health business

Eli Lilly and Co said on Tuesday it is considering the sale of its Elanco animal health business and expressed optimism that its rejected rheumatoid arthritis drug would pass muster with U.S. regulators when it resubmits its application.

Oct 24 2017

Competitors

Earnings vs. Estimates